Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2009
  • Online publication date: May 2010

Chapter 25 - Nonsurgical treatment of male infertility:

Export citation
Summary
This chapter reviews the current concepts and ongoing controversies regarding the pathophysiology, diagnosis, significance, and treatment of the varicocele. Varicocele may also affect reactive oxygen species generation, rendering the testicle and the sperm unable to handle oxidative stress, and resulting in reactive oxygen species buildup. Toxic agents and heavy metals accumulate in tissues undergoing apoptosis, several investigators has examined testicular tissue heavy-metal content in men with varicocele. A pencil-probe Doppler stethoscope has been advocated as an adjunctive tool in the examination of the varicocele. Ultrasonography has become an increasingly useful modality in the diagnosis of varicocele. Surgical varicocelectomy is the cornerstone of varicocele therapy. Several surgical approaches are available to accomplish varicocelectomy. The approaches include the scrotal approach, the subinguinal approach, the inguinal approach, the retroperitoneal approach, and the laparoscopic approach. Azoospermia has generally been regarded as a contraindication to varicocelectomy.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Infertility in the Male
  • Online ISBN: 9780511635656
  • Book DOI: https://doi.org/10.1017/CBO9780511635656
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

[1] DubinL, AmelarRD. Etiologic factors in 1294 consecutive cases of male infertility. Fertil Steril 1971; 22: 469–74.
[2] GreenbergSH, LipshultzLI, WeinAJ. Experience with 425 subfertile male patients. J Urol 1978; 119: 507–10.
[3] CollinsJA, WrixonW, JanesLB, WilsonEH. Treatment-independent pregnancy among infertile couples. N Engl J Med 1983; 309: 1201–6.
[4] ReadMD, SchniedenH. Variations in sperm count in oligozoospermic or asthenozoospermic patients. Andrologia 1978; 10: 52–5.
[5] MatsumotoAM, KarpasAE, BremnerWJ. Chronic human chorionic gonadotropin administration in normal men: Evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man. J Clin Endocrinol Metab 1986; 62: 1184.
[6] De KretserDM, BurgerHG, FortuneD, et al. Hormonal, histological and chromosomal studies in adult males with testicular disorders. J Clin Endocrinol Metab 1972; 35: 392–401.
[7] SchellenTMCM. Clomiphene citrate in male infertility. Int J Fertil 1982; 27: 136–45.
[8] MellingerRC, ThompsonRJ. The effect of clomiphene citrate in male infertility. Fertil Steril 1966; 17: 94–103.
[9] HellerCG, RowleyMJ, HellerGV. Clomiphene citrate: a correlation of its effect on sperm concentration and morphology, total gonadotropins, ICSH, estrogen and testosterone excretion, and testicular cytology in normal men. J Clin Endocrinol Metab 1969; 29: 638–49.
[10] PaulsonDF, HammondCB, de Vere WhiteR, WiebeRH. Clomiphene citrate: pharmacologic treatment of hypofertile male. Urology 1977; 9: 419–21.
[11] FossGL, TindallVR, BirkettJP. The treatment of subfertile men with clomiphene citrate. J Reprod Fertil 1973; 32: 167–70.
[12] PaulsonDF. Cortisone acetate versus clomiphene citrate in pre-germinal idiopathic oligospermia. J Urol 1979; 121: 432–4.
[13] RönnbergL. The effect of clomiphene citrate on different sperm parameters and serum hormone levels in preselected infertile men: a controlled double-blind cross-over study. Int J Androl 1980; 3: 479–86.
[14] AbelBJ, CarswellG, EltonR, et al. Randomised trial of clomiphene citrate treatment and vitamin C for male infertility. Br J Urol 1982; 54: 780–4.
[15] WangC, ChanCW, WongKK, YeungKK. Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 1983; 40: 358–65.
[16] MicicS, DotlicR. Evaluation of sperm parameters in clinical trial with clomiphene citrate of oligospermic men. J Urol 1985; 133: 221–2.
[17] SokolRZ, SteinerBS, BustilloM, PetersenG, SwerdloffRS. A controlled comparison of the efficacy of clomiphene citrate in male infertility. Fertil Steril 1988; 49: 865–70.
[18] CheckJH, ChaseJS, NowrooziK, WuCH, AdelsonHG. Empirical therapy of the male with clomiphene in couples with unexplained fertility. Int J Fertil 1989; 34: 120–2.
[19] World Health Organization. A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. Int J Androl 1992; 15: 299–307.
[20] WielandRG, AnsariAH, KleinDE, et al. Idiopathic oligospermia: control observations and response to cisclomiphene. Fertil Steril 1972; 23: 471–4.
[21] WillisKJ, LondonDR, BevisMA, et al. Hormonal effects of tamoxifen in oligospermic men. J Endocrinol 1977; 73: 171–8.
[22] TörökL. Treatment of oligospermia with tamoxifen (open and controlled studies). Andrologia 1985; 17: 497–501.
[23] AinMelkY, BelisleS, CarmelM, Jean-PierreT. Tamoxifen citrate therapy in male infertility. Fertil Steril 1987; 48: 113–17.
[24] KrauseW, Holland-MoritzH, SchrammP. Treatment of idiopathic oligozoospermia with tamoxifen – a randomized controlled study. Int J Androl 1992; 15: 14–18.
[25] ClarkRV, SherinsRJ. Clinical trial of testolactone for treatment of idiopathic male infertility [abstract]. J Androl 1983; 4: 31.
[26] ClarkRV, SherinsRJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone: results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 1989; 10: 240–7.
[27] BardinCW, RossGT, LipsettMB. Site of action of clomiphene citrate in men: a study of the pituitary–Leydig cell axis. J Cell Endocrinol 1967; 27: 1558–64.
[28] PaulsonDF. Clomiphene citrate in the management of male hypofertility: predictors for treatment selection. Fertil Steril 1977; 28: 1226–9.
[29] ShanisB, CheckJH, BollendorfA. Adverse effect of clomiphene citrate on sperm morphology. Arch Androl 1991; 27: 109–11.
[30] HusseinA, OzgokY, RossL, NiederbergerC. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. J Androl 2005; 26: 787–91.
[31] LeePA. The occurrence of gynecomastia upon withdrawal of clomiphene citrate treatment for idiopathic oligospermia. Fertil Steril 1980; 34: 285–6.
[32] NilssonA, NilssonS. Testicular germ cell tumors after clomiphene therapy for subfertility. J Urol 1985; 134: 560–2.
[33] ChamberlainRA, CummingDC. Pulmonary embolism during clomiphene therapy for infertility in a male: a case report. Int J Fertil 1986; 31: 198–9.
[34] AkinJW. The use of clomiphene citrate in the treatment of azoospermia secondary to incomplete androgen resistance. Fertil Steril 1993; 59: 223–4.
[35] ComhaireF. Treatment of oligospermia with tamoxifen. Int J Fertil 1976; 21: 232–8.
[36] BartschG, ScheiberK. Tamoxifen treatment in oligozoospermia. Eur Urol 1981; 7: 283–7.
[37] BriganteC, MottaG, FusiF, ColettaMP, BusaccaM. Treatment of idiopathic oligozoospermia with tamoxifen. Acta Eur Fertil 1985; 16: 361–4.
[38] BuvatJ, ArdaensK, LemaireA, et al. Increased sperm count in 25 cases of idiopathic normogonadotropic oligospermia following treatment with tamoxifen. Fertil Steril 1983; 39: 700–3.
[39] DannerCH, FrickJ, MaierF. Results of treatment with tamoxifen in oligozoospermic men. Andrologia 1983; 15: 584–7.
[40] DonyJM, SmalsAG, RollandR, FauserBC, ThomasCM. Effect of lower versus higher doses of tamoxifen on pituitary-gonadal function and sperm indices in oligozoospermic men. Andrologia 1985; 17: 369–78.
[41] Lewis-JonesDI, LynchRV, MachinDC, DesmondAD. Improvement in semen quality in infertile males after treatment with tamoxifen. Andrologia 1987; 19: 86–90.
[42] NociI, CheloE, SaltarelliO, Donati CoriG, ScarselliG. Tamoxifen and oligospermia. Arch Androl 1985; 15: 83–8.
[43] SchiefersteinG, AdamW, ArmannJ, et al. Therapeutic results with tamoxifen in oligozoospermia. I. Remarks on mode of action and metabolism based on clinical findings and laboratory investigations. Andrologia 1987; 19: 113–18.
[44] SchillWB, LandthalerM. Tamoxifen treatment of oligozoospermia. Andrologia 1980; 12: 546–8.
[45] SchillWB, SchillingerR. Selection of oligozoospermic men for tamoxifen treatment by an antiestrogen test. Andrologia 1987; 19: 266–72.
[46] TraubAI, ThompsonW. The effect of tamoxifen on spermatogenesis in subfertile men. Andrologia 1981; 13: 486–90.
[47] VermeulenA, ComhaireF. Hormonal effects of an antiestrogen, tamoxifen, in normal and oligospermic men. Fertil Steril 1978; 29: 320–7.
[48] AdamopoulosDA, PappaA, BillaE, et al. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 2003; 80: 914–20.
[49] MacDonaldPC, MaddenJD, BrennerPF, WilsonJD, SiiteriPK. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49: 905–16.
[50] LongcopeC, PrattJH, SchneiderSH, FinebergSE. Aromatization of androgens by muscle and adipose tissue in vitro. J Clin Endocrinol Metab 1978; 46: 146–52.
[51] VigerskyRA, GlassAR. Effects of delta1-testolactone on the pituitary–testicular axis in oligospermic men. J Clin Endocrinol Metab 1981; 52: 897–902.
[52] JarowJP, KirklandJ, KoritnikDR, CefaluWT. Effect of obesity and fertility status on sex steroid levels in men. Urology 1993; 42: 171–4.
[53] SchlegelPN, RamanJD. Aromatase inhibitors for male infertility. J Urol 2002; 167: 624–9.
[54] WhitcombRW, CrowleyWF. Male hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am 1993; 22: 125–43.
[55] WangC, DahlKD, LeungA, ChanSY, HsuehAJ. Serum bioactive follicle-stimulating hormone in men with idiopathic azoospermia and oligospermia. J Clin Endocrinol Metab 1987; 65: 629–33.
[56] GlassSJ, HollandHM. Treatment of oligospermia with large doses of human chorionic gonadotropin. Fertil Steril 1963; 14: 500–6.
[57] LyttonB, MrouehA. Treatment of oligospermia with urinary human menopausal gonadotropin: a preliminary report. Fertil Steril 1966; 17: 696–700.
[58] DanezisJM, BatrinosML. The effect of human postmenopausal gonadotropins on infertile men with severe oligospermia. Fertil Steril 1967; 18: 788–800.
[59] LunenfeldB, MorA, ManiM. Treatment of male infertility. I. Human gonadotropins. Fertil Steril 1967; 18: 581–92.
[60] TroenP, YaniharT, NankinH, et al. Assessment of gonadotropin therapy in infertile males. In: RosenbergE, PaulsenCA, eds. The Human Testis. New York, NY: Plenum Press, 1970.
[61] MehanDJ, ChehvalMJ. Human chorionic gonadotropin in the treatment of the infertile man. J Urol 1982; 128: 60–3.
[62] SherinsRJ. Clinical aspects of treatment of male infertility with gonadotropins: testicular response of some men given HCG with and without Pergonal. In: ManciniRE, MartiniL, eds. Male Fertility and Sterility. New York, NY: Academic Press, 1974.
[63] HomonnaiZT, PeledM, PazGF. Changes in semen quality and fertility in response to endocrine treatment of subfertile men. Gynecol Obstet Invest 1978; 9: 244–55.
[64] DubinL, AmelarRD. Varicocelectomy as therapy in male infertility: a study of 504 cases. Fertil Steril 1975; 26: 217–20.
[65] AcostaAA, KhalifaE, OehningerS. Pure human follicle stimulating hormone has a role in the treatment of severe male infertility by assisted reproduction: Norfolk’s total experience. Hum Reprod 1992; 7: 1067–72.
[66] Ben-ShlomoI, BiderD, DorJ, et al. Failure to fertilize in vitro in couples with male factor infertility: what next? Fertil Steril 1992; 58: 187–9.
[67] MolloyD, HarrisonK, BreenT, HennesseyJ. The predictive value of idiopathic failure to fertilize on the first in vitro fertilization attempt. Fertil Steril 1991; 56: 285–9.
[68] KnuthUA, HöniglW, Bals-PratschM, SchleicherG, NieschlagE. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: A placebo-controlled, double blind trial. J Clin Endocrinol Metab 1987; 65: 1081–7.
[69] BadenochDF, WaxmanJ, BoormanL, et al. Administration of a gonadotropin releasing hormone analogue in oligozoospermic infertile males. Acta Endocrinol (Copenh) 1988; 117: 265–7.
[70] CrottazB, SennA, ReymondMJ, et al. Follicle-stimulating hormone bioactivity in idiopathic normogonadotropic oligoasthenozoospermia: Double-blind trial with gonadotropin-releasing hormone. Fertil Steril 1992; 57: 1034–43.
[71] AafjesJH, van der VijverJC, BrugmanFW, SchenckPE. Double-blind crossover treatment with mesterolone and placebo of subfertile oligozoospermic men: value of testicular biopsy. Andrologia 1983; 15: 531–5.
[72] World Health Organization. Mesterolone and idiopathic male infertility: a double-blind study. Int J Androl 1989; 12: 254–64.
[73] ComhaireF. Treatment of idiopathic testicular failure with high-dose testosterone undecanoate: a double-blind pilot study. Fertil Steril 1990; 54: 689–93.
[74] GerrisJ, ComhaireF, HellemansP, PeetersK, SchoonjansF. Placebo-controlled trial of high-dose mesterolone treatment of idiopathic male infertility. Fertil Steril 1991; 55: 603–7.
[75] SchillWB. Recent progress in pharmacological therapy of male subfertility: a review. Andrologia 1979; 11: 77–107.
[76] NamikiM, NakamuraM, OkuyamaA, et al. Testicular follicle stimulating hormone receptors and effectiveness of human menopausal gonadotrophin–human chorionic gonadotrophin treatment in infertile men. Clin Endocrinol (Oxf) 1986; 25: 495–500.
[77] LiuL, ChaudhariN, CorleD, SherinsRJ. Comparison of pulsatile subcutaneous gonadotropin-releasing hormone and exogenous gonadotropins in the treatment of men with isolated hypogonadotropic hypogonadism. Fertil Steril 1988; 49: 302–8.
[78] SchwarzsteinL, AparicioNJ, SchallyAV. D-tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia. Int J Androl 1982; 5: 171–8.
[79] AparicioNJ, SchwarzsteinL, TurnerEA, et al. Treatment of idiopathic normogonadotropic oligoasthenospermia with synthetic luteinizing hormone-releasing hormone. Fertil Steril 1976; 27: 549–55.
[80] MatsumiyaK, KitamuraM, KishikawaH, et al. A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia. Int J Urol 1998; 5: 361–3.
[81] McCullaghEP, McGurlFJ. Further observations on the clinical use of testosterone propionate. J Urol 1939; 42: 1265–7.
[82] TurnerTT, JonesCE, HowardsSS, et al. On the androgen microenvironment of maturing spermatozoa. Endocrinology 1984; 115: 1925–32.
[83] AlènM, ReiniläM, VihkoR. Response of serum hormones to androgen administration in power athletes. Med Sci Sports Exerc 1985; 17: 354–9.
[84] AlènM, SuominenJ. Effect of androgenic and anabolic steroids on spermatogenesis in power athletes. Int J Sports Med 1984; 5 (suppl): 189–92.
[85] ClericoA, FerdeghiniM, PalomboC, et al. Effect of anabolic treatment on the serum levels of gonadotropins, testosterone, prolactin, thyroid hormones and myoglobin of male athletes under physical training. J Nucl Med Allied Sci 1981; 25: 79–88.
[86] JarowJP, LipshultzLI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med 1990; 18: 429–31.
[87] SantulliR, SprandoRL, AwoniyiCA, EwingLL, ZirkinBR. To what extent can spermatogenesis be maintained in the hypophysectomized adult rat testis with exogenously administered testosterone? Endocrinology 1990; 126: 95–101.
[88] TurnerTT, HowardsSS, GleavyJL. On the maintenance of male fertility in the absence of native testosterone secretion: Site-directed hormonal therapy in the rat. Fertil Steril 1990; 54: 149–56.
[89] BrownJS. The effect of orally administered androgens on sperm motility. Fertil Steril 1975; 26: 305–8.
[90] UrryRL, CockettAtk. Treating the subfertile male patient: improvement in semen characteristics after low dose androgen therapy. J Urol 1976; 116: 54–5.
[91] HellerCG, NelsonWO, HillIB, et al. Improvement in spermatogenesis following depression of the human testis with testosterone. Fertil Steril 1950; 1: 415–22.
[92] CharnyCW. The use of androgens for human spermatogenesis. Fertil Steril 1959; 10: 557–70.
[93] CharnyCW, GordonJA. Testosterone rebound therapy: a neglected modality. Fertil Steril 1978; 29: 64–8.
[94] LamensdorfH, CompereD, BegleyG. Testosterone rebound therapy in the treatment of male infertility. Fertil Steril 1975; 26: 469–72.
[95] RowleyMJ, HellerCG. The testosterone rebound phenomenon in the treatment of male infertility. Fertil Steril 1972; 23: 498–504.
[96] JunglingML, BungeRG. The treatment of spermatogenic arrest with arginine. Fertil Steril 1976; 27: 282–3.
[97] UehlingDT. Low-dose cortisone for male infertility. Fertil Steril 1978; 29: 220–1.
[98] HellstromWJ, SchachterJ, SweetRL, McClureRD. Is there a role for Chlamydia trachomatis and genital mycoplasma in male infertility? Fertil Steril 1987; 48: 337–9.
[99] HovattaO, KoskimiesAI, RantaT, StenmanUH, SeppäläM. Bromocriptine treatment of oligospermia: a double blind study. Clin Endocrinol 1979; 11: 377–82.
[100] SchillWB. Improvement of sperm motility in patients with asthenozoospermia by kallikrein treatment. Andrologia 1975; 20: 61–3.
[101] SchillWB, Braun-FalcoO, HaberlandGL. The possible role of kinins in sperm motility. Int J Fertil 1974; 19: 163–7.
[102] SchillWB. Treatment of idiopathic oligozoospermia by kallikrein: results of a double-blind study. Arch Androl 1979; 2: 163–70.
[103] GlezermanM, LunenfeldE, PotashnikG, et al. Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial. Fertil Steril 1993; 60: 1052–6.
[104] KeckC, BehreHM, JockenhövelF, NieschlagE. Ineffectiveness of kallikrein in treatment of idiopathic male infertility: a double-blind, randomized, placebo-controlled trial. Hum Reprod 1994; 9: 325–9.
[105] BarkayJ, Harpaz-KerpelS, Ben-EzraS, GordonS, ZuckermanH. The prostaglandin inhibitor effect of antiinflammatory drugs in the therapy of male infertility. Fertil Steril 1984; 42: 406–11.
[106] LenziA, CulassoF, GandiniL, LombardoF, DonderoF. Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility. Hum Reprod 1993; 8: 1657–62.
[107] HomonnaiZT, ShilonM, PazG. Evaluation of semen quality following kallikrein treatment. Gynecol Obstet Invest 1978; 9: 132–8.
[108] BartkeA, KupferD, DalterioS. Prostaglandins inhibit testosterone secretion by mouse testes in vitro. Steroids 1976; 28: 81–8.
[109] AbbatielloER, KaminskyM, WeisbrothS. The effect of prostaglandins and prostaglandin inhibitors on spermatogenesis. Int J Fertil 1975; 20: 177–82.
[110] CohenMS, ColinMJ, GolimbuM, HotchkissRS. The effects of prostaglandins on sperm motility. Fertil Steril 1977; 28: 78–85.
[111] LenziA, LombardoF, GandiniL, CulassoF, DonderoF. Glutathione therapy for male infertility. Arch Androl 1992; 29: 65–8.
[112] BurgerM, SikkaSC, BivalacquaTJ, LambDJ, HellstromWJ. The effect of sildenafil on human sperm motion and function from normal and infertile men. Int J Impot Res 2000; 12: 229–34.
[113] EbischIM, PierikFH, De JongFH, et al. Does folic acid and zinc sulphate intervention affect endocrine parameters and sperm characteristics in men? Int J Androl 2006; 29: 339–45.
[114] WongWY, MerkusHM, ThomasCM, et al. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2002; 77(3): 491–8.
[115] AgarwalA, SharmaRK, NallellaKP, et al. Reactive oxygen species as an independent marker of male factor infertility. Fertil Steril 2006; 86: 878–85.
[116] MostafaT, TawadrousG, RoajaMM, et al. Effect of smoking on seminal plasma ascorbic acid in infertile and fertile males. Andrologia 2006; 38: 221–4.
[117] SierensJ, HartleyJA, CampbellMJ, LeathemAJ, WoodsideJV. In vitro isoflavone supplementation reduces hydrogen peroxide-induced DNA damage in sperm. Teratog Carcinog Mutagen 2002; 22: 227–34.
Cancel
Confirm
×